Aster DM Healthcare Limited has submitted its quarterly compliance certificate to stock exchanges, confirming adherence to SEBI depositories regulations for the quarter ended March 31, 2026. The healthcare company filed the mandatory certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.

Regulatory Compliance Submission

The company submitted the compliance certificate to both major stock exchanges on April 7, 2026. The submission details are outlined below:

Certificate Issuance and Verification

MUFG Intime India Private Limited, formerly known as Link Intime India Private Limited, issued the confirmation certificate in its capacity as the company's registrar and share transfer agent. The certificate, dated April 4, 2026, confirms that all securities received from depository participants for dematerialisation during the quarter were properly processed.

The registrar confirmed that:

• Securities received for dematerialisation were accepted or rejected within prescribed timelines
• Security certificates were mutilated and cancelled after due verification
• Depository names were substituted in the register of members as registered owners
• All securities comprised in the certificates have been listed on relevant stock exchanges

Corporate Governance Framework

Hemish Purushottam, Company Secretary and Compliance Officer (Membership No: A24331), signed the submission on behalf of Aster DM Healthcare Limited. The digital signature was applied on April 7, 2026, at 17:10:48 IST, ensuring proper authentication of the regulatory filing.

SEBI Regulation 74(5) Compliance

Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 mandates that companies submit quarterly confirmation certificates regarding dematerialisation processes. This requirement ensures transparency in the conversion of physical securities to electronic form and maintains investor protection standards.

The successful submission demonstrates Aster DM Healthcare's commitment to maintaining regulatory compliance and corporate governance standards. The certificate confirms that all dematerialisation activities during the quarter were conducted in accordance with SEBI guidelines and prescribed timelines.

Aster DM Healthcare Limited has issued a regulatory disclosure regarding the publication of newspaper advertisements for its upcoming National Company Law Tribunal (NCLT) hearing concerning the proposed amalgamation with Quality Care India Limited.

Regulatory Compliance and Publication Details

The company published mandatory newspaper advertisements on April 2, 2026, in compliance with Regulations 30 and 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The advertisements appeared in two publications to ensure comprehensive coverage:

NCLT Order and Amalgamation Scheme

The newspaper publication follows an order dated March 23, 2026, issued by the Hon'ble National Company Law Tribunal. The order pertains to the Scheme of Amalgamation amongst Quality Care India Limited and Aster DM Healthcare Limited, involving their respective shareholders and creditors.

The scheme represents a significant corporate restructuring initiative that requires regulatory approval and stakeholder consultation through the established legal framework.

Accessibility and Transparency Measures

To ensure maximum transparency and accessibility, the company has made the newspaper publication available on its official website. Stakeholders can access the complete documentation at the dedicated merger section: https://www.asterdmhealthcare.in/investors/aster-qcil-merger/scheme-of-merger .

Corporate Governance Framework

The disclosure was signed by Hemish Purushottam, Company Secretary and Compliance Officer (Membership No. A24331), demonstrating the company's commitment to proper corporate governance procedures. The communication was addressed to both major stock exchanges:

This regulatory filing ensures that all stakeholders, including investors, creditors, and regulatory authorities, are properly informed about the upcoming NCLT proceedings and can participate in the legal process as required under applicable corporate laws.